| Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes M van Eijk, RJ Boosman, AH Schinkel, ADR Huitema, JH Beijnen Cancer Chemotherapy and Pharmacology 84 (3), 487-499, 2019 | 81 | 2019 |
| ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration‐resistant prostate cancer patients: A phase Ib study MAC Vermunt, DGJ Robbrecht, LA Devriese, JM Janssen, B Thijssen, ... Cancer Reports 4 (4), e1367, 2021 | 10 | 2021 |
| The influence of docetaxel schedule on treatment tolerability and efficacy in patients with metastatic breast cancer: a systematic review and meta-analysis of randomized … M van Eijk, MAC Vermunt, E van Werkhoven, EA Wilthagen, ... BMC cancer 22 (1), 1-10, 2022 | 6 | 2022 |
| Development of a population pharmacokinetic/pharmacodynamic model for various oral paclitaxel formulations co-administered with ritonavir and thrombospondin-1 based on data … M van Eijk, H Yu, E Sawicki, VA de Weger, B Nuijen, TPC Dorlo, ... Cancer Chemotherapy and Pharmacology 90 (1), 71-82, 2022 | 1 | 2022 |
| Time above threshold plasma concentrations as pharmacokinetic parameter in the comparison of oral and intravenous docetaxel treatment of breast cancer tumors M van Eijk, JH Beijnen, ADR Huitema Anti-Cancer Drugs 34 (2), 281-289, 2023 | | 2023 |
| Investigating the influence of relevant pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of orally administered docetaxel combined with ritonavir M van Eijk, D Pluim, TPC Dorlo, S Marchetti, ADR Huitema, JH Beijnen The Pharmacogenomics Journal 21 (3), 336-345, 2021 | | 2021 |
